22. Medical Psychedelics Working Group Q&A with Professor Jo Neill
On July 14th 2020, the UK’s leading independent scientific body on drugs has launched the Drug Science Medical Psychedelics Working Group. Building off the success of the Medical Cannabis Working Group, the Medical Psychedelics Working Group is a consortium of Drug Science experts, leading academics, researchers and policy specialists, supported by industry partners. The group’s aim is to create a rational and enlightened approach to psychedelic research and clinical treatment. The group will explore innovation within the psychedelic space with a specific focus on how psychedelics can be integrated into primary and secondary healthcare. Evidence-based science, sharing data, and strong partnerships are keys to success for the psychedelic community. The purpose of this group is to break down the barriers of 50 years of medical censorship by creating a rational and enlightened approach to psychedelic research and clinical treatment, ensuring the UK is a world leader in psychedelic medicine.
Jo Neill is Professor of Psychopharmacology at the University of Manchester (Division of Pharmacy & Optometry). She is Chair of the Medical Psychedelics Working Group for Drug Science and a committee member, a scientific advisor for Heroic Hearts UK and the Conservative Drug Policy Reform Group. She is co-founder of b-neuro, a University based Contract Research Organisation developing new treatments for mental illness through animal models. Jo is past President of the British Association for Psychopharmacology (President 2016-2018). She served on the Research Excellence Framework panel for Unit of Assessment 3 (Allied Health Professions, Dentistry, Nursing and Pharmacy) in 2014. Jo is working with Policy at Manchester to educate the public about the urgent need for drug law reform and suspension of Schedule 1 restrictions to enable research into the medicinal properties of currently illegal drugs.